What changed in this filing

/stocks — the workspaceLOADING

Item 1A. Risk Factors

2023-08-11 compared with 2023-05-12 · 32 added, 3 removed, 4 unchanged (90% of the section changed)

a smaller reporting company, we are not required to provide disclosure pursuant to this item in this Form 10-Q.

However, you should carefully

consider the “Risk Factors” included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, for a

discussion of important factors that could materially affect our business, financial condition and/or operating results.

However, as of the date

of this Quarterly Report, other than as set forth below, there have been no material changes with respect to those risk factors previously

disclosed under “Risk Factors” included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as

filed with the Securities and Exchange Commission on March 13, 2023 (the “Form 10-K”).

The following should be carefully

considered, together with other information in this Quarterly Report on Form 10-Q, our Form 10-K, and our other filings with the SEC

before making investment decisions regarding our common stock.

results of our research and development efforts are uncertain and there can be no assurance they will enhance the commercial success

of our products.

believe that we will need to incur additional research and development expenditures to improve the capabilities of our BF-RhodoLED ®

lamps to better fulfill the needs of dermatologists and may also incur research and development expenditures to develop new products.

The products we are developing and may develop in the future may not be technologically successful.

At this time, we have limited internal

research and development personnel, which makes us dependent on consulting relationships.

addition, the length of our product development cycle may be greater than we originally expected, and we may experience delays in product

If our resulting products are not technologically successful, they may not achieve market acceptance or compete effectively

with our competitors’ products and services.

is substantial doubt about our ability to continue as a “going concern.”

connection with our assessment of going concern considerations under applicable accounting standards, the Company’s management

has determined that our growth plans, upcoming inventory purchases and a final settlement payment to DUSA Pharmaceuticals, Inc.

substantial doubt exists about our ability to continue as a going concern through approximately one year from the date the unaudited

condensed financial statements included in Item 1.

“Financial Statements” were issued.

The future viability of the

Company is dependent on its ability to continue to execute its growth plan and raise additional capital or find alternative methods

of financing to fund its operations.

There can be no guarantee that the actions presently being taken by the Company will be

successful in raising additional capital or finding alternative methods of financing.

If the Company is not successful in these endeavors, it would likely have a material adverse effect on the Company’s business, results

of operations and financial condition.

additional discussion of the risks and uncertainties that affect our business, see “Item 1A.

Risk Factors” included in our

Unregistered Sales of Equity Securities and Use of Proceeds.

2 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 1A. Risk Factors